Probiotic products in Canada with clinical evidence: What can gastroenterologists recommend?

Canadian Journal of Gastroenterology

Volumn 22, Issue 2, 2008, Pages 169-176

  Reid, Gregor ^a   Anukam, Kingsley ^a   Koyama, Tara ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Canada; Gastroenterology; Prevention; Probiotics; Treatment

Indexed keywords

ACTIVIA YOGURT; ALIGN; AMOXICILLIN; ANTIBIOTIC AGENT; BACID; BIO K PLUS CL1285; CLARITHROMYCIN; FEM DOPHILUS; FLORASTOR; JAMIESON LACTOBACILLUS ACIDOPHILUS; LACIDOFIL; LACTIBIANE; NATREL PRO; OASIS HEALTH BREAK WITH PROBIOTICS; OMEPRAZOLE; PLACEBO; PROBIOTIC AGENT; PROBIOTIC FROZEN YOGURT; TINIDAZOLE; TUZEN; UNCLASSIFIED DRUG; VSL3; YOGACTIVE CEREAL; YOPTIMAL IMMUNI PLUS;

CANADA; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FLORA; IRRITABLE COLON; MEDICAL SPECIALIST; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; DIGESTIVE SYSTEM DISEASE; DRUG APPROVAL;

CANADA; DIGESTIVE SYSTEM DISEASES; DRUG APPROVAL; HUMANS; PROBIOTICS;

EID: 42449131487     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/843892     Document Type: Review

References (74)

1. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. (Version current at January 21, 2008).
2. Leach JD. Evolutionary perspective on dietary intake of fibre and colorectal cancer. Eur J Clin Nutr 2007;61(1):140-2.
3. Martins FS, Rodrigues AC, Tiago FC, et al. Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype typhimurium and stimulates the immune system in gnotobiotic and conventional mice. J Med Microbiol 2007; 56:352-9.
4. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007;13:35-7.
5. Saavedra JM. Use of probiotics in pediatrics: Rationale, mechanisms of action, and practical aspects. Nutr Clin Pract 2007;22:351-65.
6. Zocco MA, Ainora ME, Gasbarrini G, Gasbarrini A. Bacteroides thetaiotaomicron in the gut: Molecular aspects of their interaction. Dig Liver Dis 2007;39:707-12.
7. Metchnikoff E. The Prolongation of Life. Optimistic Studies, New York: Putman's Sons, 1908;161-83.
8. Brummel T, Ching A, Seroude L, Simon AF, Benzer S. Drosophila lifespan enhancement by exogenous bacteria. Proc Natl Acad Sci U S A 2004;101:12974-9
9. Sechi LA, Mura M, Tanda E, Lissia A, Fadda G, Zanetti S. Mycobacterium avium sub. paratuberculosis in tissue samples of Crohn's disease patients. New Microbiol 2004;27:75-7.
10. Ryan P, Kelly RG, Lee G, et al. Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am J Gastroenterol 2004;99:1539-43.
11. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002;123:689-99.
12. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004;99:2376-84.
13. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999;44:812-8.
14. Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:675-83.
15. Ohge H, Furne JK, Springfield J, Rothenberger DA, Madoff RD, Levitt MD. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005;48:469-75.
16. Stebbings S, Munro K, Simon MA, et al. Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology (Oxford) 2002;41:1395-401.
17. Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis 2006;19:475-84.
18. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 2006;44:4136-41.
19. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 1998;10:59-62.
20. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096-101.
21. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM, for the Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006;131:445-50.
22. Quigley EM. Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol 2006;101:334-5.
23. Riordan SM, Kim R. Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol 2006;22:669-73.
24. Rhodes DY, Wallace M. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 2006;8:327-32.
25. FAO/WHO. Guidelines for the evaluation of probiotics in food. Report of a joints FAO/WHO Working Group on drafting guidelines for the evaluation of probiotics in food. (Version current at December 18, 2007).
26. Reid G. The importance of guidelines in the development and application of probiotics. Curr Pharm Des 2005;11:11-6.
27. Hughes VL, Hillier SL. Microbiologic characteristics of Lactobacillus products used for colonization of the vagina. Obstet Gynecol 1990;75:244-8.
28. Zhong W, Millsap K, Bialkowska-Hobrzanska H, Reid G. Differentiation of Lactobacillus species by molecular typing. Appl Environ Microbiol 1998;64:2418-23.
29. Hamilton-Miller JM, Shah S, Winkler JT. Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr 1999;2:223-9.
30. Temmerman R, Scheirlinck I, Huys G, Swings J. Culture-independent analysis of probiotic products by denaturing gradient gel electrophoresis. Appl Environ Microbiol 2003;69:220-6.
31. Ljungh A, Wadstrom T. Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol 2006;7:73-89.
32. Reid G. Safe and efficacious probiotics: What are they? Trends Microbiol 2006;14:348-52.
33. Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am 2006;35:355-65.
34. Reid G, Sanders ME, Gaskins HR, et al. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003;37:105-18.
35. Takahashi O, Noguchi Y, Omata F, Tokuda Y, Fukui T. Probiotics in the prevention of traveler's diarrhea: Meta-analysis. J Clin Gastroenterol 2007;41:336-7.
36. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: A meta-analysis of randomized controlled trials. J Pediatr 2006;149:367-72
37. Can M, Besirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med Sci Monit 2006;12:PI19-22.
38. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: A randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005;21:583-90.
39. Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic ( Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 2006;12:4557-60.
40. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8.
41. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: An emerging infectious disease. Clin Infect Dis 2005;40:1625-34.
42. McFarland LV. Diarrhoea associated with antibiotic use. BMJ 2007;335:54-5.
43. Dendukuri N, Brophy J. Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am J Gastroenterol 2007;102;201.
44. Lewis S. Response to the article: McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gasroenterol 2006.101:812-22. Am J Gastroenterol 2007;102:201-2.
45. Segarra-Newnham M. Probiotics for Clostridium difficile-associated diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother 2007;41:1212-21.
46. Reid G. Safety of Lactobacillus strains as probiotic agents. Clin Infect Dis 2002;35:349-50.
47. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002;35:1155-60.
48. Salminen MK, Tynkkynen S, Rautelin H, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: A randomized, placebo-controlled, crossover study. HIV Clin Trials 2004;5:183-91.
49. Anukam KC, Osazuwa EO, Osadolor BE, Bruce AW, Reid G. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol 2007. (In press)
50. Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007;149:470-9.
51. McFarland LV. Response to Drs Ramnarace and Dendukuri. Am J Gastroenterol 2007;102:202-4.
52. Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Ann Med 1990;22:57-9.
53. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999;135:564-8.
54. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: A meta-analysis. Pediatrics 2002;109(4):678-84.
55. Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr Infect Dis J 2002;21:417-9.
56. Teitelbaum JE. Probiotics and the treatment of infectious diarrhea. Pediatr Infect Dis J 2005;24:267-8.
57. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: A rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007;19:166-72.
58. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
59. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90.
60. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
61. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687-96.
62. Miki K, Urita Y, Ishikawa F, et al. Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans. J Dairy Sci 2007;90:2630-40.
63. Lionetti E, Miniello VL, Castellaneta SP, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial. Aliment Pharmacol Ther 2006;24:1461-8.
64. Gionchetti P, Rizzello F, Campieri M. Probiotics in gastroenterology. Curr Opin Gastroenterol 2002;18:235-9.
65. Chapman TM, Plosker CL, Figgitt DP. VSL#3 probiotic mixture: A review of its use in chronic inflammatory bowel diseases. Drugs 2006;66:1371-87
66. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
67. Kuhbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006;55:833-41.
68. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC. Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: An in vivo study using intestinal perfusion. Am J Clin Nutr 1992;55:78-80.
69. Berrada N, Lemeland JF, Laroche G, Thouvenot P, Piaia M. Bifidobacterium from fermented milks: Survival during gastric transit. J Dairy Sci 1991;74:409-13.
70. Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: A double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002;16:587-93.
71. Ivanko O. Lacidofil in the prevention of Clostridium difficile diarrhea in children. Proceedings of the Institute Rosell Conference, 2005. Italy, September 7 to 8, 2005:22-24.
72. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004;72(9):5308-14.
73. Kim SO, Sheik HI, Ha SD, Martins A, Reid G. G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages. Cell Microbiol 2006;8:1958-71.
74. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-20.